Physician profile
Haroon Akhtar
NPI 1164614764
$3,262.36
in general payments reported to CMS, 2019-2025
31 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $285 · 2021: $744 · 2022: $653 · 2023: $521 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $427.11 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $422.88 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $318.66 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $291.65 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $266.49 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $233.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.85 | 2019-2023 | Jardiance |
| Pfizer INC. | $149.44 | 2019-2025 | |
| Esperion Therapeutics, INC. | $141.05 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.33 | 2022-2023 | |
| Amarin Pharma, INC. | $86.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $66.46 | 2019-2022 | |
| Amgen INC. | $64.35 | 2019-2025 | Evenity |
| Sanofi Pasteur INC. | $54.33 | 2019-2020 | |
| Exact Sciences Corporation | $53.67 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.12 | 2019 | |
| Genentech USA, INC. | $34.29 | 2019 | |
| Merck Sharp & Dohme LLC | $32.83 | 2019-2025 | Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $32.15 | 2019-2023 | Trintellix |
| Adlon Therapeutics L.P. | $28.32 | 2019 | |
| Astellas Pharma US INC | $25.52 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.31 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $22.41 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $20.75 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.93 | 2021 | |
| Allergan, INC. | $17.60 | 2019 | |
| Eisai INC. | $16.25 | 2021 | |
| Medtronic, INC. | $15.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.15 | 2021 | |
| Shire North American Group INC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.